Hospira company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

hospira.com

Founded Year

2004

Stage

Acq - P2P | Acquired

Valuation

$0000 

About Hospira

Hospira is a provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness by improving patient and caregiver safety while reducing healthcare costs.

Hospira Headquarter Location

275 N Field Dr

Lake Forest, Illinois, 60045,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Hospira

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hospira is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Hospira Patents

Hospira has filed 134 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Sedatives
  • Amines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/22/2019

1/18/2022

Medical equipment, Occupational safety and health, Drug delivery devices, Dosage forms, Radiopharmaceuticals

Grant

Application Date

4/22/2019

Grant Date

1/18/2022

Title

Related Topics

Medical equipment, Occupational safety and health, Drug delivery devices, Dosage forms, Radiopharmaceuticals

Status

Grant

Latest Hospira News

Familial incidence linked to risk for IBD in first-degree relatives

Apr 25, 2022

Disclosures: Halfvarson reports financial relationships with AbbVie, Aqilion, Celgene, Celltrion, Ferring, Hospira, Janssen, MEDA, Medivir, MSD, Olink Proteomics, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillots Pharma, Vifor Pharma and UCB. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Individuals who have a sibling with inflammatory bowel disease had a fourfold-increased risk for IBD compared with the general population, according to research published in Alimentary Pharmacology & Therapeutics. “A family history of IBD is a proxy for an individual’s genetic and, in part, environmental risk of developing the disease and has long been recognized as the strongest risk factor for IBD. ... From an etiological point of view, studies of familial aggregation of IBD may shed light on the impact of genetic and environmental risk factors,” Jonas F. Halfvarson, MD, PhD, of the department of gastroenterology at Orebro University in Sweden, and colleagues wrote. “This motivates studies that provide precise estimates of the future risk of IBD in first-degree relatives of newly diagnosed IBD patients.” In a nationwide, case-control study, Halfvarson and colleagues used Swedish national registers to identify 50,667 patients diagnosed with IBD between 2003 and 2017 who had at least one first-degree relative with IBD and compared them with 506,720 controls from the general population, matching for age, sex, birth year and county of residence. Studied outcomes included calculated odds for patients with IBD to have a relative with IBD and incidence of future IBD among relatives. Compared with controls, patients with IBD were more likely to have a first-degree relative with IBD, regardless of disease type, including a mother (3% vs. 0.9%; OR = 3.5; 95% CI, 3.3-3.7), father (2.9% vs. 0.8%; OR = 3.5; 95% CI, 3.3-3.7), full sibling (5.3% vs. 1.5%; OR = 3.6; 95% CI, 3.4-3.8) or child (2.4% vs. 0.9%; OR = 2.6; 95% CI, 2.4-2.8) with IBD. Pediatric-onset Crohn’s disease (OR = 10.6; 95% CI, 8.2-13.5) and ulcerative colitis (OR = 8.4; 95% CI, 6.4-10.9) carried the highest odds. The association strength increased with the number of affected first-degree relatives. In addition, researchers noted the 10-year cumulative incidence of IBD was 1.7% among full siblings of patients with IBD vs. 0.4% among full siblings of control patients. “This large nationwide, population-based study provides novel information on several aspects of familial IBD, is of importance for both researchers and clinicians and can help tailor future screening interventions,” Halfvarson and colleagues concluded. “Both age at IBD diagnosis of the index patient and age of the healthy first-degree relative should be taken into account when planning future screening programs and preventive interventions in IBD.” Read more about

  • When was Hospira founded?

    Hospira was founded in 2004.

  • Where is Hospira's headquarters?

    Hospira's headquarters is located at 275 N Field Dr, Lake Forest.

  • What is Hospira's latest funding round?

    Hospira's latest funding round is Acq - P2P.

  • Who are the investors of Hospira?

    Investors of Hospira include Pfizer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.